Tvardi Therapeutics Inc (TVRD)

Common Shares

Sell: $2.80|Buy: $3.30|Change: 0.06 (-2.03%)

This investment is classed as a complex financial instrument. These types of investments carry higher risks and can be more difficult to understand. They are intended for experienced investors who have a good understanding of how these investments work. Read more about complex financial instruments.

Open

$2.93

Previous close

$2.96

Trade high

$2.97777

Volume

51,468

Year high

$43.65

Year low

$2.75

Dividend yield

–

Market capitalisation

$27.21 mn

P/E ratio

19.53

ISIN

US1407553072

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA SIPP

Share price

Performance 10/04/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Tvardi Therapeutics Inc	- 2.03
More...

Company profile

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.